Puma Biotechnology Stock Forecast, Price & News

-0.33 (-3.23 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.64 million shs
Average Volume345,924 shs
Market Capitalization$398.78 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PBYI News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Puma Biotechnology logo

About Puma Biotechnology

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.61 out of 5 stars

Medical Sector

437th out of 2,100 stocks

Pharmaceutical Preparations Industry

211th out of 830 stocks

Analyst Opinion: 2.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions

Is Puma Biotechnology a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Puma Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBYI, but not buy additional shares or sell existing shares.
View analyst ratings for Puma Biotechnology
or view top-rated stocks.

What stocks does MarketBeat like better than Puma Biotechnology?

Wall Street analysts have given Puma Biotechnology a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Puma Biotechnology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Puma Biotechnology's next earnings date?

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Puma Biotechnology

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its quarterly earnings data on Thursday, May, 6th. The biopharmaceutical company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.11. The biopharmaceutical company earned $98.20 million during the quarter, compared to the consensus estimate of $74.55 million. Puma Biotechnology had a negative trailing twelve-month return on equity of 318.22% and a negative net margin of 9.77%. The company's revenue for the quarter was up 91.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.43) earnings per share.
View Puma Biotechnology's earnings history

How has Puma Biotechnology's stock price been impacted by Coronavirus (COVID-19)?

Puma Biotechnology's stock was trading at $9.27 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PBYI stock has increased by 6.6% and is now trading at $9.88.
View which stocks have been most impacted by COVID-19

What price target have analysts set for PBYI?

4 equities research analysts have issued 1-year target prices for Puma Biotechnology's shares. Their forecasts range from $9.00 to $15.00. On average, they expect Puma Biotechnology's stock price to reach $11.50 in the next year. This suggests a possible upside of 16.4% from the stock's current price.
View analysts' price targets for Puma Biotechnology
or view top-rated stocks among Wall Street analysts.

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the following people:
  • Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 51, Pay $5.69M)
  • Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 52, Pay $1.63M)
  • Mr. Douglas Hunt B.Sc., FRAPS, Sr. VP of Regulatory Affairs, Medical Writing & Project Management (Age 56, Pay $2.14M)
  • Mr. Jeffrey Jerome Ludwig, Chief Commercial Officer (Age 55, Pay $4.61M)
  • Mr. Mariann Ohanesian, Sr. Director of Investor Relations
  • Charon Spencer Sr., VP of HR
  • Dr. Alvin F. Wong, Sr. VP of Clinical Science & Pharmacology

Who are some of Puma Biotechnology's key competitors?

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and (CELG).

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Deerfield Management Company L.P. Series C (9.34%), Fred Alger Management LLC (8.99%), BlackRock Inc. (7.68%), Renaissance Technologies LLC (3.94%), Palo Alto Investors LP (3.45%) and Acadian Asset Management LLC (3.01%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Maximo F Nougues, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends for Puma Biotechnology

Which major investors are selling Puma Biotechnology stock?

PBYI stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Deerfield Management Company L.P. Series C, BNP Paribas Arbitrage SA, Ikarian Capital LLC, Renaissance Technologies LLC, Bank of Montreal Can, Credit Suisse AG, and Jupiter Asset Management Ltd.. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Maximo F Nougues, and Richard Paul Bryce.
View insider buying and selling activity for Puma Biotechnology
or view top insider-selling stocks.

Which major investors are buying Puma Biotechnology stock?

PBYI stock was purchased by a variety of institutional investors in the last quarter, including Globeflex Capital L P, Worth Venture Partners LLC, Fred Alger Management LLC, Citigroup Inc., Goldman Sachs Group Inc., Envestnet Asset Management Inc., BlackRock Inc., and Nuveen Asset Management LLC.
View insider buying and selling activity for Puma Biotechnology
or or view top insider-buying stocks.

How do I buy shares of Puma Biotechnology?

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $9.88.

How much money does Puma Biotechnology make?

Puma Biotechnology has a market capitalization of $398.78 million and generates $225.10 million in revenue each year. The biopharmaceutical company earns $-59,990,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

How many employees does Puma Biotechnology have?

Puma Biotechnology employs 267 workers across the globe.

What is Puma Biotechnology's official website?

The official website for Puma Biotechnology is

Where are Puma Biotechnology's headquarters?

Puma Biotechnology is headquartered at 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]

This page was last updated on 6/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.